Navigation Links
Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
Date:11/12/2007

about Verus is available on the company's corporate website at http://www.veruspharm.com.

Verus(R) is a registered trademark of Verus Pharmaceuticals, Inc.

Forward-Looking Statements

Verus Pharmaceuticals cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus' business including, without limitation, statements about: its ability to identify appropriate acquisition, licensing, or co-development and/or promotion candidates in the future or be able to take advantage of the opportunities it identifies; difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products; unexpected performance or side effects of its products that could delay or prevent development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Company Contact: Media Contact:

Robert W. Keith Amy Caterina

President & Chief Executive Officer Corporate Communications

Verus Pharmaceuticals, Inc. Verus Pharmaceuticals, Inc.

rkeith@veruspharm.com
'/>"/>

SOURCE Verus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... , ... The Celebrity Dresses is currently running a promotion through July 30th. ... have the opportunity to get 10% discount on orders that are over $100. , ... to use coupon codes or remember redemption codes. , There is a low ...
(Date:7/2/2015)... ... 2015 , ... The American Association of Poison Control Centers ... Stat (S.O.S.) Act of 2015 on June 23, 2015. Together with the Senate ... drug overdose – especially of heroin and opioid medication – by expanding the ...
(Date:7/2/2015)... ... 02, 2015 , ... “ LIFX ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... light bulbs on the market. , According to the U.S. Department of Energy, it’s ...
(Date:7/2/2015)... ... July 02, 2015 , ... The ZAC Foundation, a national leader ... with important lessons on how to stay water safe with the help of a ... authored by The ZAC Foundation co-founders, follows Zeke’s water safety journey. Zeke, who ...
(Date:7/2/2015)... ... July 02, 2015 , ... CleanItSupply.com, ... it has reached an agreement to acquire eRubbermaid.com, an Internet retailer of ... Rubbermaid Commercial Products on the web today. , “eRubbermaid.com’s search ...
Breaking Medicine News(10 mins):Health News:Celebrity Fashion Summer Party Dresses on sale at TheCelebrityDresses.com 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 2Health News:AAPCC Supports the Stop Overdose Stat Act of 2015 3Health News:The Most Versatile Smart Light Bulbs were featured on NewsWatch Television 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 2Health News:The ZAC Foundation Kicks Off Summer and July 4th Weekend with Complimentary Children’s E-Book on Water Safety 3Health News:CleanItSupply.com Acquires eRubbermaid.com 2
... of the first to implement a 3D cardiac ultrasound machine ... operate.// The machine is a computer designed to show all ... echocardiography system. The artificial intelligence of the system can be ... precise preferences to cardiac surgeons even before they decide on ...
... to researchers from Harvard School of Public Health (HSPH), ... risk of having Parkinson’s disease.// ,Parkinson’s disease ... in their middle ages. Some symptoms of the condition ... a posture. The disease affects the brain cells that ...
... University, while presenting a paper at the AAAS Meeting in ... cooking them to into mashed textures may be one of ... formed. Thus congenital bad shaped teeth may be a direct ... are in bad shape, when compared with teeth of the ...
... to latest research rheumatoid arthritis patients have twice the ... heart's ability // to pump blood, compared to those ... showed patients with rheumatoid arthritis are at an increased ... arthritis, and this risk continues throughout the course of ...
... in the air in many inner-city homes could be ... say researchers. ,According to researchers children living in ... found in mouse urine that is circulating in the ... sensitivity to mice, just as it does for laboratory ...
... a pilot study in New York, air pollution due to ... of the fetus in the womb.// The research was done ... Mailman School of Public Health at Columbia University, US. ... to air pollution due to polycyclic aromatic hydrocarbons (PAH) that ...
Cached Medicine News:
(Date:7/3/2015)... DALLAS , July 3, 2015 ... report "Cardiac Monitoring & Cardiac Rhythm Management Market ... Output Monitoring, Defibrillator, Implantable Cardioverter Defibrillator, Dual Chamber ... published by MarketsandMarkets, the global Cardiac Monitoring (CM) ... poised to reach $26,646.5 Million by 2020 from ...
(Date:7/3/2015)... 2015 A global continuing medical ... and thyroid disorders in Latin America ... conference dedicated to these diseases.      (Logo: ... Manage Hypertension Online and Manage Thyroid ... EXCEMED - combine the world,s top expertise with ...
(Date:7/3/2015)... , July 3, 2015  Obsidian HDS, the ... an online service for the management of data on ... today that PharmaShine now includes the 2014 Open Payments ... Medicare Services on June 30. The data disclosed on ... transactions between industry and providers totaling $6.49 billion and ...
Breaking Medicine Technology:Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 2Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 3Cardiac Monitoring (CM) and Cardiac Rhythm Management (CRM) Devices Market Worth $26,646.5 Million by 2020 4Combating Three Major Chronic Diseases in Latin America With Medical Education 2New Open Payments (Sunshine Act) Data Now Searchable on PharmaShine 2
... Phase 3 Once Weekly Investigational Diabetes Therapy Also Improved ... from Exenatide Taken Twice a Day, SAN FRANCISCO, ... Eli Lilly and Company (NYSE: LLY ), and ... a 52-week open-label clinical,study that showed the durable efficacy ...
... VIEW, Calif., June 9 Alexza,Pharmaceuticals, Inc. (Nasdaq: ... Phase 2a proof-of-concept clinical trial with AZ-002 (Staccato(R),alprazolam) ... not meet its two,primary endpoints, which were the ... panic attack and the effect of AZ-002 on ...
Cached Medicine Technology:After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Extra-large 3.2mm channel allows excellent suction with EndoTherapy devices in place....
... bronchofiberscope yet. The BF-3C40's distal end measures ... the previous model. It also offers better ... to the use of extra-fine optical fibers ... size by 70 percent. Images are clearer, ...
Facilitates one-lung ventilation when using dual lumen endobronchial tubes....
Medicine Products: